Table 3.
Cefiderocol Susceptibilities Among MBL-Producing Enterobacterales
| MBL Enzyme | No. of Isolates | %S (MIC50/90 [mg/L] or Range MIC [mg/L]) | Ref. |
|---|---|---|---|
| CFDC | |||
| MBL | 64a | 70 (N/A) | 124 |
| NDM | 49b | 89.8 (1/4) | 154 |
| 12c | N/A (4/8) | 155 | |
| 61d | 72.1 (4/8) | 77 | |
| VIM | 12b | 91.7 (≤0.12/0.25) | 154 |
| 27c | 100 (1/4) | 155 | |
| 47d | 95.7 (0.5/4) | 77 | |
| IMP | 8b | 87.5 (≤0.125–16)e | 154 |
| 15d | 100 (0.25/2) | 77 |
Notes: Susceptible criteria: CFDC ≤4 mg/L based on CLSI interpretive criteria. aE. coli isolates obtained from the US, Asia-West Pacific, Europe, and Latin America. MBL category includes: NDM (n=53), VIM (n=3), IMP (n=8). bClinical isolates collected from the International Health Management Associates (IMHA) (Schaumburg, IL) between 2009 and 2011. cMeropenem-resistant (MIC ≥ 4 mg/L) Enterobacterales collected from 99 hospitals in North America and Europe as part of the SIDERO-WT-2014 surveillance study. dRepresentative carbapenemase producing Enterobacterales from Public Health England’s Antimicrobial Resistance and Healthcare-Associated Infections (AMRHAI) Reference Unit between 2008–2018. eMIC90 not available for <10 isolates.
Abbreviations: %S, percent susceptible; CFDC, cefiderocol; N/A, not available.